339 related articles for article (PubMed ID: 24718890)
1. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer.
Kerr KM; Bubendorf L; Edelman MJ; Marchetti A; Mok T; Novello S; O'Byrne K; Stahel R; Peters S; Felip E;
Ann Oncol; 2014 Sep; 25(9):1681-1690. PubMed ID: 24718890
[TBL] [Abstract][Full Text] [Related]
2. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up.
Vansteenkiste J; Crinò L; Dooms C; Douillard JY; Faivre-Finn C; Lim E; Rocco G; Senan S; Van Schil P; Veronesi G; Stahel R; Peters S; Felip E;
Ann Oncol; 2014 Aug; 25(8):1462-74. PubMed ID: 24562446
[TBL] [Abstract][Full Text] [Related]
3. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer.
Eberhardt WE; De Ruysscher D; Weder W; Le Péchoux C; De Leyn P; Hoffmann H; Westeel V; Stahel R; Felip E; Peters S;
Ann Oncol; 2015 Aug; 26(8):1573-88. PubMed ID: 25897013
[TBL] [Abstract][Full Text] [Related]
4. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease.
Besse B; Adjei A; Baas P; Meldgaard P; Nicolson M; Paz-Ares L; Reck M; Smit EF; Syrigos K; Stahel R; Felip E; Peters S; ;
Ann Oncol; 2014 Aug; 25(8):1475-84. PubMed ID: 24669016
[TBL] [Abstract][Full Text] [Related]
5. Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study.
Gridelli C; de Marinis F; Ardizzoni A; Novello S; Fontanini G; Cappuzzo F; Grossi F; Santo A; Cortinovis D; Favaretto A; Lorusso V; Galetta D; Siena S; Bettini A; Iurlaro M; Caprioli A;
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1783-93. PubMed ID: 24903964
[TBL] [Abstract][Full Text] [Related]
6. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010.
Felip E; Gridelli C; Baas P; Rosell R; Stahel R;
Ann Oncol; 2011 Jul; 22(7):1507-1519. PubMed ID: 21536661
[TBL] [Abstract][Full Text] [Related]
7. 1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer.
Stahel R; Thatcher N; Früh M; Le Péchoux C; Postmus PE; Sorensen JB; Felip E;
Ann Oncol; 2011 Sep; 22(9):1973-1980. PubMed ID: 21727198
[TBL] [Abstract][Full Text] [Related]
8. ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer.
Gerber DE; Oxnard GR; Govindan R
Clin Pharmacol Ther; 2015 May; 97(5):447-50. PubMed ID: 25677079
[TBL] [Abstract][Full Text] [Related]
9. Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
Garrido P; Conde E; de Castro J; Gómez-Román JJ; Felip E; Pijuan L; Isla D; Sanz J; Paz-Ares L; López-Ríos F
Clin Transl Oncol; 2020 Jul; 22(7):989-1003. PubMed ID: 31598903
[TBL] [Abstract][Full Text] [Related]
10. [Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology].
López-Ríos F; Paz-Ares L; Sanz J; Isla D; Pijuan L; Felip E; Gómez-Román JJ; de Castro J; Conde E; Garrido P
Rev Esp Patol; 2020; 53(3):167-181. PubMed ID: 32650968
[TBL] [Abstract][Full Text] [Related]
11. Predictive markers in lung cancer: a few hints for the practicing pathologist.
Barbareschi M; Barberis M; Buttitta F; Doglioni C; Fiorentino M; Fontanini G; Franco R; Marchetti A; Rossi G; Troncone G
Pathologica; 2018 Mar; 110(1):29-38. PubMed ID: 30259911
[TBL] [Abstract][Full Text] [Related]
12. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer.
Passaro A; Leighl N; Blackhall F; Popat S; Kerr K; Ahn MJ; Arcila ME; Arrieta O; Planchard D; de Marinis F; Dingemans AM; Dziadziuszko R; Faivre-Finn C; Feldman J; Felip E; Curigliano G; Herbst R; Jänne PA; John T; Mitsudomi T; Mok T; Normanno N; Paz-Ares L; Ramalingam S; Sequist L; Vansteenkiste J; Wistuba II; Wolf J; Wu YL; Yang SR; Yang JCH; Yatabe Y; Pentheroudakis G; Peters S
Ann Oncol; 2022 May; 33(5):466-487. PubMed ID: 35176458
[TBL] [Abstract][Full Text] [Related]
13. Clinical and Cost Implications of Universal Versus Locally Advanced-Stage and Advanced-Stage-Only Molecular Testing for Epidermal Growth Factor Receptor Mutations and Anaplastic Lymphoma Kinase Rearrangements in Non-Small Cell Lung Carcinoma: A Tertiary Academic Institution Experience.
Sauter JL; Butnor KJ
Arch Pathol Lab Med; 2016 Apr; 140(4):358-61. PubMed ID: 27028394
[TBL] [Abstract][Full Text] [Related]
14. Recommendations for the analysis of ALK gene rearrangements in non-small-cell lung cancer: a consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology.
Marchetti A; Ardizzoni A; Papotti M; Crinò L; Rossi G; Gridelli C; Barberis M; Maiorano E; Normanno N; Taddei GL; Scagliotti G; Clemente C; Pinto C
J Thorac Oncol; 2013 Mar; 8(3):352-8. PubMed ID: 23407559
[TBL] [Abstract][Full Text] [Related]
15. Does Immunohistochemistry Represent a Robust Alternative Technique in Determining Drugable Predictive Gene Alterations in Non-Small Cell Lung Cancer?
Rossi G; Ragazzi M; Tamagnini I; Mengoli MC; Vincenzi G; Barbieri F; Piccioli S; Bisagni A; Vavala T; Righi L; Novello S; Gelsomino F; Tiseo M
Curr Drug Targets; 2017; 18(1):13-26. PubMed ID: 25901525
[TBL] [Abstract][Full Text] [Related]
16. Cytology samples and molecular biomarker testing in lung cancer-advantages and challenges.
Canberk S; Engels M
Virchows Arch; 2021 Jan; 478(1):45-57. PubMed ID: 33389149
[TBL] [Abstract][Full Text] [Related]
17. Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease.
Hiley CT; Le Quesne J; Santis G; Sharpe R; de Castro DG; Middleton G; Swanton C
Lancet; 2016 Sep; 388(10048):1002-11. PubMed ID: 27598680
[TBL] [Abstract][Full Text] [Related]
18. [The Guideline for Diagnosis and Treatment of Chinese Patients with sensitizing EGFR Mutation or ALK Fusion Gene-Positive Non-Small Cell Lung Cancer (2015 Version)].
;
Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):796-9. PubMed ID: 26813604
[No Abstract] [Full Text] [Related]
19. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
Lindeman NI; Cagle PT; Beasley MB; Chitale DA; Dacic S; Giaccone G; Jenkins RB; Kwiatkowski DJ; Saldivar JS; Squire J; Thunnissen E; Ladanyi M; College of American Pathologists International Association for the Study of Lung Cancer and Association for Molecular Pathology
J Mol Diagn; 2013 Jul; 15(4):415-53. PubMed ID: 23562183
[TBL] [Abstract][Full Text] [Related]
20. Future Perspectives in Detecting
Ferreira D; Miranda J; Martins-Lopes P; Adega F; Chaves R
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33916986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
